Pages that link to "Q71393819"

The following pages link to New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse (Q71393819):

Displaying 26 items.

• Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study (Q33419682) (← links)
• Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study (Q33437503) (← links)
• Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma (Q33455133) (← links)
• Phase I trial of 4'-deoxydoxorubicin given weekly (Q33478900) (← links)
• Phase I trial with 4'-deoxydoxorubicin (esorubicin). (Q33480323) (← links)
• Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice (Q33554035) (← links)
• Phenotypic screening in cancer drug discovery - past, present and future (Q34429484) (← links)
• Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo (Q37348039) (← links)
• Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth (Q37602060) (← links)
• Anthracycline analogs: the past, present, and future (Q39480685) (← links)
• Human tumor xenografts as model for drug testing (Q39563484) (← links)
• Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature (Q39641690) (← links)
• The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review (Q39818231) (← links)
• Cytotoxic effect of dose and schedule on normal murine hematopoietic progenitor cells following the administration of 4'-deoxydoxorubicin (Q41981162) (← links)
• Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs (Q42116442) (← links)
• Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach (Q44628999) (← links)
• Phase I study of 4'-deoxydoxorubicin (esorubicin) in children with malignant solid tumors. (Q54349318) (← links)
• Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. (Q54372706) (← links)
• Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study (Q68461439) (← links)
• Phase II study of 4'-deoxydoxorubicin in advanced colorectal cancer (Q69570379) (← links)
• Activity of cancer chemotherapeutic agents against human colorectal carcinomas grown as primary tissue culture (Q69753271) (← links)
• Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC) (Q69835639) (← links)
• Phase I study with 4'-deoxydoxorubicin (Q70712585) (← links)
• Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety (Q71682095) (← links)
• Evaluation of new anthracycline analogs with the human tumor stem cell assay (Q72025307) (← links)
• Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin) (Q93672448) (← links)